CAMPNasdaqPharmaceutical PreparationsFiscal year ends December 31

Camp4 Therapeutics Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$3.14−0.03 (-0.95%)

Close on Oct 19, 2026

Market cap: $181.90M
P/E (TTM): –
Dividend yield: 0.00%

Camp4 Therapeutics Corp income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Revenue	3.50	0.65	0.35
Research & Development	38	39	41
General & Administrative	17	15	12
Operating Expenses	56	54	52
Operating Income	-53	-53	-52
Interest & Investment Income	2.17	1.33	2.81
Other Non-Operating Income	-28	1.30	2.59
Asset Impairment Charges	0.50	0	–
Gain (Loss) on Sale of Assets	-0.26	0	–
Income Tax Expense	0	0	0
Net Income	-80	-52	-49
Net Income to Common	-80	-52	–
EPS (Basic)(per share)	-2.65	-11.04	-124.80
EPS (Diluted)(per share)	-2.65	-11.04	-124.80
Shares Outstanding (Basic, Weighted)(shares)	30	4.69	0.39
Shares Outstanding (Diluted, Weighted)(shares)	30	4.69	0.39
Dividend per Share(per share)	0.00	0.00	–
EBITDA	-51	-51	-50

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -1254.2%
Net margin: -2543.7%
Return on equity, FY2025: -145.1%

Financial strength

Current ratio: 4.70
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 451.4%

Valuation

P/E ratio: –
Price to sales: 43.14
Price to book: –
Dividend yield: 0.00%